Hiddo J.L. Heerspink
Researcher Next ID · RN-022770
Researcher · Medicine
New South Wales Department of Health
North Sydney, Netherlands
- Works count
- 1,095
- Citation count
- 67,628
- H-index
- 121
- i10-index
- 517
Research interests
Publications
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
New England Journal of Medicine · 2025 · https://doi.org/10.1056/nejmoa2410659
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00569-x
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)02302-4
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Kidney International · 2022 · https://doi.org/10.1016/j.kint.2022.06.008
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)02074-8
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
The Lancet · 2021 · 10.1016/s0140-6736(21)00536-5
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
Kidney International · 2021 · 10.1016/j.kint.2021.03.033
Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)
European Journal of Heart Failure · 2020 · 10.1002/ejhf.1713
Dapagliflozin in Patients with Chronic Kidney Disease
New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2024816
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
The Lancet Diabetes & Endocrinology · 2020 · 10.1016/s2213-8587(20)30369-7
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1811744
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
The Lancet Diabetes & Endocrinology · 2019 · 10.1016/s2213-8587(19)30180-9
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Nephrology Dialysis Transplantation · 2019 · https://doi.org/10.1093/ndt/gfz290
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Nephrology Dialysis Transplantation · 2019 · https://doi.org/10.1093/ndt/gfz290
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
Diabetologia · 2019 · 10.1007/s00125-019-4859-4
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)30772-x
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
American Journal of Kidney Diseases · 2019 · 10.1053/j.ajkd.2019.06.009
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
The Lancet Diabetes & Endocrinology · 2019 · https://doi.org/10.1016/s2213-8587(19)30256-6
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
The Lancet Diabetes & Endocrinology · 2019 · 10.1016/s2213-8587(18)30314-0
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
The Lancet Diabetes & Endocrinology · 2019 · 10.1016/s2213-8587(18)30314-0
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Kidney International · 2018 · 10.1016/j.kint.2017.12.027
Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis
European Heart Journal · 2018 · https://doi.org/10.1093/eurheartj/ehy100
Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis
European Heart Journal · 2018 · https://doi.org/10.1093/eurheartj/ehy100
Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis
European Heart Journal · 2018 · https://doi.org/10.1093/eurheartj/ehy100
Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate
Kidney International · 2018 · https://doi.org/10.1016/j.kint.2018.01.009
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
The Lancet · 2017 · 10.1016/s0140-6736(17)30788-2
Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
Journal of the American Society of Nephrology · 2017 · 10.1681/asn.2016060666
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
Circulation · 2016 · https://doi.org/10.1161/circulationaha.116.021887
Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure
JAMA · 2016 · https://doi.org/10.1001/jama.2015.18202
A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury
American Journal of Kidney Diseases · 2015 · https://doi.org/10.1053/j.ajkd.2015.02.337
The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial
The Lancet Diabetes & Endocrinology · 2015 · https://doi.org/10.1016/s2213-8587(15)00261-2
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
New England Journal of Medicine · 2013 · 10.1056/nejmoa1306033
Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes
Diabetes Obesity and Metabolism · 2013 · 10.1111/dom.12127
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
The Lancet · 2013 · https://doi.org/10.1016/s0140-6736(13)60595-4
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
The Lancet · 2012 · https://doi.org/10.1016/s0140-6736(12)61350-6
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials
The Lancet · 2009 · 10.1016/s0140-6736(09)60212-9
Current projects
No projects listed.